Investigators at the National Cancer Institute (NCI) have discovered an adjuvanted mucosal subunit vaccine to prevent SARS-CoV-2 transmission and infection. The mucosal vaccine is composed of a novel molecular adjuvant nanoparticle that induces robust humoral and cellular immunity, as well as trained innate immunity with enhanced protection against respiratory SARS-CoV-2 exposure. The technology is available for potential licensing or collaborative research to co-develop these therapeutic targets.
The National Cancer Institute (NCI) seeks research co-development partners and/or licensees for the sulfatide analog, C24:2, that is capable of activating tumor killing type II NKT cells and reducing cancer metastasis to the lung.
Scientists at the National Eye Institute (NEI) have developed a technology for a 3D bioprinting process. Through the process, an artificial blood retinal barrier (BRB) is constructed that may be used as a graft to potentially replace BRB tissues that are lost or damaged in many ocular disorders. The printed tissue structures might be therapeutically useful for grafts or as model systems to test function and physiological responses to drugs or other variables introduced into the system.
Recent research has demonstrated that neoantigen-specific T-cell receptors (TCRs) can be isolated from a cancer patient’s lymphocytes. These TCRs may be used to engineer populations of tumor-reactive T cells for cancer immunotherapies. Obtaining sequences of these functional TCRs is a critical initial step in preparing this type of personalized cancer treatment; however, current methods are time-consuming and labor-intensive. Scientists at the National Cancer Institute (NCI) have developed a rapid and robust method of isolating the sequences of mutation-specific TCRs to alleviate these issues; they seek licensing and/or co-development research collaborations for the development of a method for isolating the sequences of tumor-reactive TCRs. For collaboration opportunities, please contact Steven A. Rosenberg, M.D., Ph.D. at firstname.lastname@example.org.
To date, there is no FDA-approved therapeutic vaccine for human papillomavirus (HPV). Researchers at the National Cancer Institute (NCI) have discovered agonist epitopes for the development of an HPV therapeutic vaccine. NCI is seeking parties interested in licensing and/or co-developing HPV agonist epitopes that enhance the activation of cytotoxic T lymphocytes (CTL) and lysis of human tumor cells.
The National Cancer Institute is seeking parties interested in licensing human monoclonal antibodies (mAbs) that bind to death receptor 4 ("DR4"). The tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and its functional receptors, DR4 and DR5, have been recognized as promising targets for cancer treatment.
There is a need to develop compounds that can sensitize cancer cells to apoptosis inducing ligands, such as poly I:C and TRAIL. In collaboration with the University of Arizona, NCI investigators discovered a series of compounds in the withanolide family that synergistically enhance the response of cancer cells to treatment with an apoptosis-inducing ligand. The NCI seeks licensing and/or co-development research collaborations for development of withanolide E analogues for the treatment of cancer.
The National Cancer Institute's Urologic Oncology Branch seeks interested parties to co-develop antagonists to VEGF-A and hepatocyte growth factor (HGF) that block signal transduction and associated cellular responses.
Tuberculosis (TB) is an infectious disease that typically affects the lungs. Current therapies include a panel of antibiotics given over a range of 6-9 months. As a result of the expense of treatment, the extended timeframe needed for effective treatment, and the scarcity of medicines in some developing countries, patient compliance with TB treatment is very low and results in multi-drug resistant TB (MDR-TB). There remains a need for a faster, more effective treatment for TB. NCI researchers seek licensing and/or co-development of peptide inhibitors of STAT3 and IL-10 developed to treat bacterial infections such as tuberculosis. See aslo: NIH inventions E-164-2007 and E-167-2010
Chimeric antigen receptor (CAR) T cells that specifically target Glypican 2 (GPC2) are strong therapeutic candidates for patients with neuroblastoma and other GPC2-expressing cancers. The inventors at the National Cancer Institute (NCI) have developed a potent anti-GPC2 (CT3) CAR containing CD28 hinge and transmembrane domains (CT3.28H.BBζ) that is available for licensing and co-development.
Chimeric Antigen Receptor T cell (CAR-T) therapies that specifically target Signaling Lymphocyte Activation Molecule F7 (SLAMF7) are strong therapeutic candidates for patients with Multiple Myeloma (MM). SLAMF7 is highly expressed on the malignant plasma cells that constitute MM. The expression of SLAMF7 by MM cells and lack of expression on nonhematologic cells makes SLAMF7 an attractive therapeutic target for MM. Researchers at the National Cancer Institute (NCI) have invented anti- SLAMF7 CAR constructs that allow genetically-modified T cells to express both the anti-SLAMF7 antibody and a suicide gene that allows T cells to specifically recognize and kill SLAMF7-expressing cells as well as allow for on-demand and reliable elimination of anti-SLAMF7 CAR T cells. NCI seeks licensing and/or co-development partners for this invention.
Researchers at the National Cancer Institute (NCI) developed five high-affinity, fully human monoclonal antibodies targeting FLT3. Chimeric antigen receptors (CARs) have also been constructed based on the antibodies identified and tested in animal models of acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL).
The National Cancer Institute Laboratory of Molecular Biology is seeking statements of capability or interest from parties interested in licensing or collaborative research to further develop, evaluate, or commercialize antibody-based treatments of mesothelin-expressing cancers.
The National Cancer Institute (NCI) seeks research co-development partners or licensees for antisense oligonucleotides that reduce cancer cell migration and invasion. These are expected to be therapeutic against metastatic cancer.
Researchers at the National Cancer Institute (NCI) have developed aryl hydantoin heterocycles that target the androgen receptor (AR). NCI seeks research co-development partners and/or licensees to develop these compounds as therapeutics for prostate cancer. As these compounds consist of both AR agonists and antagonists, they may also be effective therapeutics for androgen dysfunctional disorders, such as androgen deficiency disorders or hyperandrogenism.
The technology is a series of modafinil analogues that bind with moderate to high affinity to the dopamine (DA) transporter (DAT). Some compounds also have affinity for the serotonin (5-HT) transporter (SERT) and/or sigma-1 receptor. The compounds retain the desired dopamine transporter affinity with greater metabolic stability over previously described unsubstituted piperazine ring analogues. Importantly, these compounds have no predicted addictive liability. Also disclosed are methods for treating substance use disorders as well as other neuropsychiatric disorders such as ADHD, depression, narcolepsy, and cognitive impairment. Researchers at the National Institute on Drug Abuse (NIDA) seek licensing and/or co-development research collaborations for further development and commercialization of the compounds.
Investigators from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) have identified five autophagy-inhibiting compounds (WX8 family) through a high-throughput screening. The NICHD seeks licensees and/or co-development partners for methods to treat cancer by administering these autophagy-inhibiting compounds.
Available for licensing from the National Cancer Institute are fully human monoclonal antibodies that were selected from the first human post-alloHSCT antibody library. The library was generated from a time point after transplantation at which antibodies to B-CLL cell surface antigens peaked, thus indicating its therapeutic value.
Researchers at the National Cancer Institute (NCI) have discovered that primary bile acids and antibiotics are a novel therapeutic for the treatment of liver cancer and liver metastases. NCI is seeking parties interested in licensing and/or co-developing primary bile acids and antibiotics that have been demonstrated in vivo to attract natural killer T (NKT) cells to the liver and inhibit tumor development.